Literature DB >> 33499103

Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39.

Vittoria Lopez1,2, Laura Schäkel1,2, H J Maximilian Schuh3, Michael S Schmidt3, Salahuddin Mirza1,2, Christian Renn1,2, Julie Pelletier4, Sang-Yong Lee1,2, Jean Sévigny4,5, Susanne Alban6, Gerd Bendas3, Christa E Müller1,2.   

Abstract

Extracellular ATP mediates proinflammatory and antiproliferative effects via activation of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly immunosuppressive and enhances tumor proliferation and metastasis. The conversion of ATP to adenosine is catalyzed by ectonucleotidases, which are expressed on immune cells and typically upregulated on tumor cells. In the present study, we identified sulfopolysaccharides from brown and red sea algae to act as potent dual inhibitors of the main ATP-hydrolyzing ectoenzymes, ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39), showing nano- to picomolar potency and displaying a non-competitive mechanism of inhibition. We showed that one of the sulfopolysaccharides tested as a representative example reduced adenosine formation at the surface of the human glioblastoma cell line U87 in a concentration-dependent manner. These natural products represent the most potent inhibitors of extracellular ATP hydrolysis known to date and have potential as novel therapeutics for the immunotherapy of cancer.

Entities:  

Keywords:  CD39; NPP1; NTPDase1; adenosine; ectonucleotidase inhibitors; fucoidan; immuno-oncology; macroalgae constituents; sulfated polysaccharides

Mesh:

Substances:

Year:  2021        PMID: 33499103      PMCID: PMC7911304          DOI: 10.3390/md19020051

Source DB:  PubMed          Journal:  Mar Drugs        ISSN: 1660-3397            Impact factor:   5.118


  53 in total

1.  A highly sensitive CE-UV method with dynamic coating of silica-fused capillaries for monitoring of nucleotide pyrophosphatase/phosphodiesterase reactions.

Authors:  Jamshed Iqbal; Sébastien A Lévesque; Jean Sévigny; Christa E Müller
Journal:  Electrophoresis       Date:  2008-09       Impact factor: 3.535

2.  Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.

Authors:  Anna Junker; Christian Renn; Clemens Dobelmann; Vigneshwaran Namasivayam; Shanu Jain; Karolina Losenkova; Heikki Irjala; Sierra Duca; Ramachandran Balasubramanian; Saibal Chakraborty; Frederik Börgel; Herbert Zimmermann; Gennady G Yegutkin; Christa E Müller; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2019-03-21       Impact factor: 7.446

3.  The promiscuous ectonucleotidase NPP1: molecular insights into substrate binding and hydrolysis.

Authors:  Vigneshwaran Namasivayam; Sang-Yong Lee; Christa E Müller
Journal:  Biochim Biophys Acta Gen Subj       Date:  2016-12-21       Impact factor: 3.770

4.  A robotics-based automated assay for inorganic and organic phosphates.

Authors:  E B Cogan; G B Birrell; O H Griffith
Journal:  Anal Biochem       Date:  1999-06-15       Impact factor: 3.365

5.  A key tyrosine substitution restricts nucleotide hydrolysis by the ectoenzyme NPP5.

Authors:  Alexei Gorelik; Antsa Randriamihaja; Katalin Illes; Bhushan Nagar
Journal:  FEBS J       Date:  2017-09-30       Impact factor: 5.542

6.  Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1.

Authors:  J Bageritz; L Puccio; R M Piro; V Hovestadt; E Phillips; T Pankert; J Lohr; C Herold-Mende; P Lichter; V Goidts
Journal:  Cell Death Differ       Date:  2014-02-14       Impact factor: 15.828

7.  Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases.

Authors:  S A Lévesque; E G Lavoie; J Lecka; F Bigonnesse; J Sévigny
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

8.  Targeting CD73 in the tumor microenvironment with MEDI9447.

Authors:  Carl M Hay; Erin Sult; Qihui Huang; Kathy Mulgrew; Stacy R Fuhrmann; Kelly A McGlinchey; Scott A Hammond; Raymond Rothstein; Jonathan Rios-Doria; Edmund Poon; Nick Holoweckyj; Nicholas M Durham; Ching Ching Leow; Gundo Diedrich; Melissa Damschroder; Ronald Herbst; Robert E Hollingsworth; Kris F Sachsenmeier
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

9.  Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1.

Authors:  Kazuki Kato; Hiroshi Nishimasu; Daisuke Oikawa; Seiichi Hirano; Hisato Hirano; Go Kasuya; Ryuichiro Ishitani; Fuminori Tokunaga; Osamu Nureki
Journal:  Nat Commun       Date:  2018-10-24       Impact factor: 14.919

Review 10.  Who Is Who in Adenosine Transport.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2018-06-14       Impact factor: 5.810

View more
  2 in total

Review 1.  E-NTPDases: Possible Roles on Host-Parasite Interactions and Therapeutic Opportunities.

Authors:  Lisvane Paes-Vieira; André Luiz Gomes-Vieira; José Roberto Meyer-Fernandes
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

2.  Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.

Authors:  Laura Schäkel; Salahuddin Mirza; Riekje Winzer; Vittoria Lopez; Riham Idris; Haneen Al-Hroub; Julie Pelletier; Jean Sévigny; Eva Tolosa; Christa E Müller
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.